Barry Kuang focuses his practice on a wide range of general corporate matters, mergers and acquisitions, venture capital financings, cross border transactions and late-stage transactions.
Enavate Sciences Co-Leads Normunity’s $75 Million Series B
January 13, 2025
Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.
Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C
January 7, 2025
Cooley advised Enavate Sciences, a top investment firm, on its participation in the $207.5 million Series C financing round of Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immunomodulators. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.
Cooley advised Lightning AI, creator of the PyTorch Lightning framework, on its $50 million equity investment from Cisco Investments, J.P. Morgan, K5 Global and NVIDIA, bringing its total funding to $103 million.
Cooley advised Opkey, a top artificial intelligence continuous test automation platform for enterprise systems, on its $47 million Series B financing. Partner Miguel Vega led the Cooley team advising Opkey.
HealthTrio Combines With mPulse and Decision Point Healthcare Solutions
December 19, 2023
Cooley advised HealthTrio, a top provider of comprehensive health management and member engagement solutions, on its strategic acquisition by mPulse, which also announced its acquisition of Decision Point Healthcare Solutions.
